Αντιυπερτασική αγωγή σε ασθενείς ενδιάμεσου καρδιαγγειακού κινδύνου;

[Argirios Argiriou]

N Engl J Med 2016; 374:2009-2020May 26, 2016DOI: 10.1056/NEJMoa1600175

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

...............
.....................

Conclusions

Therapy with candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day was not associated with a lower rate of major cardiovascular events than placebo among persons at intermediate risk who did not have cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; ClinicalTrials.gov number, NCT00468923.)

.................................................

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος